Bid, buy or donate, to raise funds for gynaecological cancer research this September:
Donate to the ‘Honour Wall' and honour your loved ones who have been touched by gynaecological cancer.
Purchase art by renowned and emerging artists throughout September.
In the fight against gynaecological cancer, every picture tells a story – of courage, of hope, of discovery.
Honour Her Campaign
Honour Her brings together renowned and community artists to tell important stories of women in support of the 6,800 Australian women diagnosed with gynaecological cancer each year, and those working hard to enable them to live better and live longer.
Gynaecological cancers are the third most common cancers in women, but they can be difficult to diagnose and have much lower survival rates than other cancers. While 92% of women survive breast cancer five years after diagnosis, this number drops to 49% for women with ovarian cancer.
Honour Her funds state-of-the-art research and clinical trials that will help change this story for the 18 women diagnosed with gynaecological cancer every day.
Ways to Honour Her
Get together and get involved to raise critical funds to support gynaecological cancer research to enable women to live better and live longer.
Purchase artwork from our virtual gallery created by leading & community artists. Starting at just $100, you’ll be securing a beautiful piece of art while supporting a great cause, with 100% of the proceeds going to Honour Her.
New for 2022, you can honour a loved one on our Honour Wall. By doing this you’ll be directly contributing to pioneering research that will enable thousands of women to live better, longer lives.
Finding the answer for ovarian cancer
Oncologist and cancer researcher Professor Kelly Anne Phillips has been trying to “answer the unanswered” for more than 25 years in pursuit of better health outcomes for women.
In her current clinical trial, supported by ANZGOG and WomenCan, she is turning her attention to a potential solution that is surprisingly simple – but could be life-changing for women affected by ovarian cancer.